Compared with primary tumors, the inhibitory effect of ASC in metastatic melanoma was gradually converted into a tumorigenic role through the improvement of NF-κB pathways and the secretion of inflammasome-medicated IL-1β43. The gene discussed is NFKB1; the disease is metastatic melanoma.